Can ablation win against partial nephrectomy and become first line therapy in cT1a renal tumours?

dc.authorid0000-0002-5009-8435
dc.authorid0000-0003-0906-4417
dc.contributor.authorSandbergen, Laura
dc.contributor.authorGüven, Selçuk
dc.contributor.authordel Pilar Laguna Pes, Maria
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:51:42Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:51:42Z
dc.date.issued2019
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı
dc.descriptionWOS: 000467768700011
dc.descriptionPubMed ID: 30308573
dc.description.abstractPurpose of review Currently, small renal masses account for the largest proportion of renal tumour and small renal cell carcinomas (RCC). Although partial nephrectomy, whenever possible, is recognized as the gold standard for treatment, thermal ablation has gained increasing attention as optional treatment in a population sector harbouring small renal masses/small RCCs. The purpose of this review is to update comparative outcomes between these two options of treatment. Recent findings Recent observational case-control and population-based cohorts applying propensity score or inverse probability treatment weighted methodology adjusting for baseline patient and tumour characteristics, compare outcomes between partial nephrectomy and thermal ablation (both cryotherapy and radiofrequency), radical nephrectomy and thermal ablation and between thermal ablation and nonsurgical management. Most of them focus on T1aRCC. Summary Comparative outcomes' evidence is limited to population-based or institutional series adjusted for baseline differences and systematic reviews. With exception of special clinical situations, thermal ablation provides similar estimated 5-year cancer and overall survival with a clear benefit in postoperative outcomes when compared to partial nephrectomy in cT1a older patients. The trade-off is more evident when thermal ablation is compared to radical nephrectomy. The advantages in terms of adverse events persist up to 1 year after treatment. Benefits are less apparent in solitary kidneys and when synchronous bilateral approaches are performed.
dc.description.sponsorshipCure for Cancer foundation (Amsterdam, the Netherlands)en_US
dc.description.sponsorshipL.S. is a PhD student supported by Cure for Cancer foundation (Amsterdam, the Netherlands).en_US
dc.identifier.citationSandbergen, L., Güven, S. ve del Pilar Laguna Pes, M. (2019). Can ablation win against partial nephrectomy and become first line therapy in cT1a renal tumours? Current Opinion in Urology, 29(1), 70-77. https://dx.doi.org/10.1097/MOU.0000000000000559
dc.identifier.doi10.1097/MOU.0000000000000559
dc.identifier.endpage77
dc.identifier.issn0963-0643
dc.identifier.issn1473-6586
dc.identifier.issue1
dc.identifier.scopusqualityQ1
dc.identifier.startpage70
dc.identifier.urihttps://dx.doi.org/10.1097/MOU.0000000000000559
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2269
dc.identifier.volume29
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams and Wilkins
dc.relation.ispartofCurrent Opinion in Urologyen_US
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectCryoablation
dc.subjectCT1a Renal Mass
dc.subjectLocalized Renal Mass
dc.subjectMinimally Invasive Surgery
dc.subjectPartial Nephrectomy
dc.subjectPercutaneous Ablation
dc.subjectRadiofrequency
dc.subjectRenal Cell Carcinoma
dc.subjectRobotic
dc.subjectSmall Renal Masses
dc.subjectThermal Ablation
dc.titleCan ablation win against partial nephrectomy and become first line therapy in cT1a renal tumours?
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Güven, Selçuk.pdf
Boyut:
291.55 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text